Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis
A live, multi-source view of Regeneron Pharmaceuticals, Inc. (REGN): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc.
Sector: Healthcare · Industry: Biotechnology · United States · 15,410 employees · regeneron.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Regeneron Pharmaceuticals, Inc. (REGN) had a market capitalization of $85.22B, a trailing P/E of 20.9 (forward 13.7), a dividend yield of 0.45% and a beta of 0.19; the shares traded in a 52-week range of $541.00 – $859.34 (51.0% over the year).
- Market cap
- $85.22B
- Enterprise value
- $77.36B
- Trailing P/E
- 20.9
- Forward P/E
- 13.7
- PEG ratio
- 1.19
- Price / book
- 2.62
- EPS (trailing)
- $39.65
- EPS (forward)
- $60.61
- Dividend yield
- 0.45%
- Payout ratio
- 9.0%
- Ex-dividend date
- 2026-08-18
- 52-week range
- $541.00 – $859.34
- 52-week change
- 51.0%
- Beta
- 0.19
- Average volume
- 851,117
- Shares outstanding
- 101.1M
- Short % of float
- 2.46%
- Profit margin
- 27.9%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Regeneron Pharmaceuticals, Inc. (REGN) last closed at $793.26 (the last completed close before that scan).
Technicals at the scan: RSI 49 (neutral territory), price -3.0% versus its 20-day average, 20-day versus 50-day average spread +9.3%, MACD histogram -7.61.
Sentiment inputs: 92% of recent Finnhub-scored headlines read bullish; StockTwits 94% bullish; analyst consensus score 68/100.
Next scheduled company event: in 47 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 1 buy and 0 sells of REGN; corporate insiders filed 0 buys and 5 sells (4 distinct filers, latest disclosure 2026-09-03). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Marion Mccourt (0B/2S), Kathryn Guarini (0B/2S), Huda Y. Zoghbi (0B/1S), Alan Armstrong (1B/0S). Who is trading what
RapidTradeView pick record
REGN has been a daily pick 3 times; 0 of 3 graded picks beat SPY over the following five trading days. Most recent: 2026-06-11, rank #2, -1.47% versus SPY (lagged). Full scoreboard
What this page covers
RapidTradeView pulls Regeneron Pharmaceuticals, Inc. (REGN) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell REGN.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.